Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

被引:14
|
作者
Sen, Fatma [1 ]
Tambas, Makbule [2 ]
Ozkaya, Kubra [2 ]
Guveli, Murat Emin [2 ]
Ciftci, Rumeysa [1 ]
Ozkan, Berker
Oral, Ethem Nezih [2 ]
Saglam, Esra Kaytan [2 ]
Saip, Pinar [1 ]
Toker, Alper [3 ]
Demir, Adalet [3 ]
Firat, Pinar [4 ]
Aydiner, Adnan [1 ]
Eralp, Yesim [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Inst Oncol, Dept Med Oncol, Istanbul, Turkey
[2] Istanbul Univ, Istanbul Fac Med, Dept Radiat Oncol, Istanbul, Turkey
[3] Istanbul Univ, Istanbul Fac Med, Dept Thorac Surg, Istanbul, Turkey
[4] Istanbul Univ, Istanbul Fac Med, Dept Pathol, Istanbul, Turkey
关键词
concomitant chemoradiotherapy; docetaxel-cisplatin; etoposide-cisplatin; locally-advanced NSCLC; lung cancer; VINORELBINE PLUS CISPLATIN; RANDOMIZED PHASE-II; 1ST-LINE TREATMENT; RADIATION-THERAPY; CONCURRENT RADIOTHERAPY; INDUCTION CHEMOTHERAPY; PLATINUM COMBINATIONS; THORACIC RADIATION; STAGE IIIA; TRIAL;
D O I
10.1097/MD.0000000000004280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Presently, there is no consensus regarding which chemotherapy regimen is best to administer with radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Herein, our aim was to compare the outcome of patients treated with either etoposide-cisplatin (EP) or docetaxel-cisplatin (DP) in this curative setting. Patients treated with either EP or DP and concurrent radiotherapy from 2004 to2012 were identified and their detailed medical records and follow-up information were obtained for analysis in this retrospective study. Survival rates were compared using Cox proportional hazards regression models with adjustments for confounding parameters provided by propensity score methods. A total of 105 patients were treated with concurrent chemoradiotherapy for LA-NSCLC (stage IIB-IIIA-IIIB). The median ages were 54 years (range, 32-70 years) and 55 years (range, 37-73 years) in the EP (n= 50) and DP (n= 55) groups, respectively. The median follow-up time was 27 months (range, 1-132 months) in the EP group and 19 months (range, 1-96 months) in DP group. There was no significant difference in baseline clinicopathologic features including age, sex, performance status, histologic subtype, and clinical TNM stages between groups. In the univariate analysis, the median overall survival of patients treated with EP was higher than that of patients treated with DP (41 vs. 20 months, P= 0.003). Multivariate analysis further revealed a survival advantage with EP compared with DP (hazard ratio [HR], 0.46; 95% confidence interval: 0.25-0.83; P= 0.009). The toxicity profile of the 2treatment groups was similar except that pulmonary toxicity was higher in the DP group (grade 3-4: 0% vs. 6%, P= 0.024). Concurrent chemoradiotherapy with EP may provide more favorable outcomes than DP and with an acceptable safety profile.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer - single institution retrospective analysis
    Lee, HW
    Choi, JH
    Lim, HY
    Park, JS
    Kim, HC
    Kang, S
    Oh, YT
    Chun, M
    Sheen, SS
    Oh, YJ
    Park, KJ
    Hwang, SC
    NEOPLASMA, 2006, 53 (01) : 30 - 36
  • [32] Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer
    Kusumoto, Sojiro
    Hirose, Takashi
    Fukayama, Motoko
    Kataoka, Daisuke
    Hamada, Kenji
    Sugiyama, Tomohide
    Shirai, Takao
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Kadokura, Mitsutaka
    Adachi, Mitsuru
    ONCOLOGY REPORTS, 2009, 22 (05) : 1157 - 1162
  • [33] Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer
    Vokes, EE
    ONCOLOGIST, 2001, 6 : 25 - 27
  • [34] Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer
    Nadiye Akdeniz
    Mehmet Küçüköner
    Muhammet Ali Kaplan
    Zuhat Urakçı
    Oğur Karhan
    Yasin Sezgin
    Erkan Bilen
    Senar Ebinç
    Fatma Teke
    Şahin Laçin
    Özkan Alan
    Özlem Ercelep
    Abdurrahman Işıkdoğan
    Perran Fulden Yumuk
    International Journal of Clinical Oncology, 2020, 25 : 2015 - 2024
  • [35] Neoadjuvant Radiotherapy/Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
    Yalman, Deniz
    BALKAN MEDICAL JOURNAL, 2015, 32 (01) : 1 - 7
  • [36] Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer
    Cascone, Tina
    Gold, Kathryn A.
    Swisher, Stephen G.
    Liu, Diane D.
    Fossella, Frank V.
    Sepesi, Boris
    Pataer, Apar
    Weissferdt, Annikka
    Kalhor, Neda
    Vaporciyan, Ara A.
    Hofstetter, Wayne L.
    Wistuba, Ignacio I.
    Heymach, John V.
    Kim, Edward S.
    William, William N., Jr.
    ANNALS OF THORACIC SURGERY, 2018, 105 (02) : 418 - 424
  • [37] A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer
    Senan, S.
    Cardenal, F.
    Vansteenkiste, J.
    Stigt, J.
    Akyol, F.
    De Neve, W.
    Bakker, J.
    Dupont, J. -M.
    Scagliotti, G. V.
    Ricardi, U.
    van Meerbeeck, J. P.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 553 - 558
  • [38] Triplet Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Patients with Recurrent or Refractory Non-small Cell Lung Cancer
    Fujimoto, Nobukazu
    Kiura, Katsuyuki
    Takigawa, Nagio
    Fujiwara, Yoshiro
    Toyooka, Shinichi
    Umemura, Shigeki
    Tabata, Masahiro
    Ueoka, Hiroshi
    Tanimoto, Mitsune
    ACTA MEDICA OKAYAMA, 2010, 64 (01) : 33 - 37
  • [39] Cardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patients
    Demkow, Urszula
    Stelmaszczyk-Emmel, Anna
    RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2013, 187 (01) : 64 - 67
  • [40] Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study
    Feliu, Jaime
    Firvida, Jose Luis
    Castro, Javier
    Madronal, Catherina
    Rodriguez-Jaraiz, Angeles
    Salgado, Mercedes
    Belda-Iniesta, Cristobal
    Casado, Enrique
    Garcia-Mata, Jesus
    Gonzalez-Baron, Manuel
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) : 403 - 409